1,196 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AGN Allergan plc. $184.29 $62.56B Downtrend
Article Searches
AbbVie Faces California Insurance Department Suit for Humira http://www.zacks.com/stock/news/323897/abbvie-faces-california-insurance-department-suit-for-humira?cid=CS-ZC-FT-323897 Sep 19, 2018 - AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.
Your Daily Pharma Scoop: Alnylam Regains, Karyopharm Positive, Teva Approved https://seekingalpha.com/article/4206899-daily-pharma-scoop-alnylam-regains-karyopharm-positive-teva-approved?source=feed_sector_healthcare Sep 18, 2018 - Alnylam had an eventful week.Karyopharm reports positive Phase 2 data.Teva’s migraine drug is approved.
Ironwood Stock Up, Heart Candidate Gets Fast Track Status http://www.zacks.com/stock/news/323183/ironwood-stock-up-heart-candidate-gets-fast-track-status?cid=CS-ZC-FT-323183 Sep 14, 2018 - The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.
Is Allergan (AGN) a Great Stock for Value Investors? http://www.zacks.com/stock/news/323101/is-allergan-agn-a-great-stock-for-value-investors?cid=CS-ZC-FT-323101 Sep 14, 2018 - Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.
Aceto 72% Target Net Gain Tops WallStar Healthcare Equities For September https://seekingalpha.com/article/4205864-aceto-72-percent-target-net-gain-tops-wallstar-healthcare-equities-september?source=feed_all_articles Sep 12, 2018 - But for PMD, Big pharma drug makers and biotech continued to top the healthcare sector by yield and broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare s
Revance Therapeutics: A New Contender In The Botox Arena https://seekingalpha.com/article/4205300-revance-therapeutics-new-contender-botox-arena?source=feed_sector_healthcare Sep 10, 2018 - Revance is a clinical-stage biotechnology company focused on the development and commercialization of botulinum toxin (Botox) products for cosmetic and therapeutic applications.Near-term catalysts inc
Breaking Down The NASH Fibrosis Market - Intercept, Genfit Primed For Potential Market Dominance https://seekingalpha.com/article/4205139-breaking-nash-fibrosis-market-intercept-genfit-primed-potential-market-dominance?source=feed_all_articles Sep 10, 2018 - By 2025, the NASH treatment market will be worth between $20-35 billion (per various estimates).Intercept Pharmaceuticals and Genfit are leading the race to develop a drug for NASH fibrosis, and Aller
Top Insider Buys Highlight for the Week of Sept. 7 http://www.gurufocus.com/news/735552/top-insider-buys-highlight-for-the-week-of-sept-7 Sep 09, 2018 - Top Insider Buys Highlight for the Week of Sept. 7, Stocks: AXP,SLB,AGN,KDP, release date:Sep 07, 2018
Allergan PLC (AGN) CEO Brent Saunders Presents at 2018 Wells Fargo Healthcare Conference (Transcript) https://seekingalpha.com/article/4204308-allergan-plc-agn-ceo-brent-saunders-presents-2018-wells-fargo-healthcare-conference?source=feed_sector_healthcare Sep 05, 2018 - Allergan PLC (NYSE:AGN) 2018 Wells Fargo Healthcare Conference Call September 05, 2018 09:05 AM ET Executives Brent Saunders - Chief Executive Officer Analysts David Maris - Wells Fargo Securities Pre
One sector is beating tech this quarter, but one technician sees a ceiling https://www.cnbc.com/2018/08/31/one-sector-is-beating-tech-this-quarter-but-one-technician-sees-a-ceiling.html Aug 31, 2018 - One sector has been tearing up the S&P 500 this quarter, rocketing to new highs, and it's not tech. Health care has been the surprise winner as the third quarter enters the home stretch.

Pages: 1234567...120

<Page 2>